EGFR inhibitors augment antitumour helper T-cell responses of HER family-specific immunotherapy

BACKGROUND: Head and neck squamous cell carcinoma (HNSCC) is a major cause of cancer-related morbidity and mortality worldwide. Epidermal growth factor receptor (EGFR)-targeted therapy is an attractive strategy alternative to conventional cancer treatments for HNSCC, but its efficacy remains controv...

Descripción completa

Detalles Bibliográficos
Autores principales: Kumai, T, Matsuda, Y, Oikawa, K, Aoki, N, Kimura, S, Harabuchi, Y, Celis, E, Kobayashi, H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3798972/
https://www.ncbi.nlm.nih.gov/pubmed/24045666
http://dx.doi.org/10.1038/bjc.2013.577

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3798972/
https://www.ncbi.nlm.nih.gov/pubmed/24045666
http://dx.doi.org/10.1038/bjc.2013.577

Ejemplares similares